Stratosvir
Stevenage, GB · 1 known investors
Stratosvir develops engineered oncolytic viruses for cancer immunotherapy, designed to selectively replicate in tumours, destroy malignant cells, and reprogram the immune system. The company's platform addresses systemic delivery barriers to enable intravenous administration for treating solid tumours and metastases.
Founders & leadership
Board
PM
Priya MandeinChairman
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- STRATOSVIR LIMITED
- Company number
- 13099988
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 24 Dec 2020
- Registered office
- 46-54 High Street, Ingatestone, CM4 9DW
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 24 Dec 2025 · next due 7 Jan 2027
Current officers · 4
- Laura Margaret Fletcher — director, appointed 10 May 2021
- Priya Mande — director, appointed 6 Nov 2023
- Juan Antonio Postigo — director, appointed 10 May 2021
- Christopher Graeme Ullman — director, appointed 24 Dec 2020
Source: Companies House public register · retrieved 6 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Stratosvir do?
- Stratosvir develops engineered oncolytic viruses for cancer immunotherapy, designed to selectively replicate in tumours, destroy malignant cells, and reprogram the immune system. The company's platform addresses systemic delivery barriers to enable intravenous administration for treating solid tumours and metastases.
- Who are Stratosvir's investors?
- Stratosvir's investors include Deep Science Ventures.
- Where is Stratosvir headquartered?
- Stratosvir is headquartered in Stevenage, GB.